[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359898-105":59,"doc-detail-359898-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-overlooked-autoantibody-repertoire-exploring-the-biomarker-potential-of-downregulated-autoantibodies-in-nsclc","The Overlooked Autoantibody Repertoire - Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC","","Autoantibodies (AAbs) act as promising cancer biomarkers, yet most AAbs show elevation and downregulated subsets remain poorly characterized. This study uses the HuProt protein microarray to screen downregulated AAbs in non-small cell lung cancer (NSCLC) serum. Indirect ELISA quantifies levels in 781 samples, while ten machine-learning algorithms build diagnostic models. An independent cohort of 353 patients supports prognostic modeling, yielding six downregulated AAbs, diagnostic performance with GBM, and Cox-linked prognostic signatures.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-overlooked-autoantibody-repertoire-exploring-the-biomarker-potential-of-downregulated-autoantibodies-in-nsclc/359898/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-overlooked-autoantibody-repertoire-exploring-the-biomarker-potential-of-downregulated-autoantibodies-in-nsclc/359898.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"To identify downregulated autoantibodies in NSCLC and evaluate their diagnostic and prognostic potential as biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were downregulated autoantibodies discovered?",{"text":117,"@type":113},"The study screened NSCLC serum using the HuProt protein microarray, followed by indirect ELISA quantification in 781 samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What modeling approaches were used and what did they show?",{"text":121,"@type":113},"Ten machine-learning algorithms were used to build diagnostic models, with gradient boosting achieving the best performance. A prognostic model was further supported by multivariate Cox regression and integration of age with AAb levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359898,1790838444,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nBasic and Clinical Immunology  \nThe Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC  \nYihao Liang1 | Hanke Ma1  | Wenke Sun1 | Ying Chen1 | Fengqi Chen1 | Yutong Li1 | Songyun Ouyang2 | Liping Dai1   \n1Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University,  \nZhengzhou, China | 2Department of Respiratory and Sleep Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China Correspondence: Liping Dai ([lpdai@zzu.edu.cn](lpdai@zzu.edu.cn))  \nReceived: 27 November 2025 | Revised: 1 February 2026 | Accepted: 4 February 2026  \nKeywords: AAbs | biomarker | diagnostic and prognosis model | downregulated AAbs | NSCLC  \nABSTRACT  \nAutoantibodies (AAbs) represent promising biomarkers in cancer. While most AAbs are elevated in cancer, a substantial subset is downregulated, and their diagnostic and prognostic potential remains largely unexplored. Here we used the HuProt protein microarray to identify downregulated AAbs in non-small cell lung cancer (NSCLC) serum. Indirect ELISA quantified serum levels in 781 samples. Ten machine learning algorithms were used to construct diagnostic models. An independent cohort of 353 NSCLC patients was used to assess prognostic value and develop a prognostic model. Six downregulated AAbs were identified, among which five AAbs (anti-HIST1H1B, anti-HIST1H1C, anti-DYDC2, anti-CAMKK2, and anti-GRPEL1) were significantly reduced in NSCLC. The gradient boosting machine (GBM) model showed the best performance for NSCLC and BPNs, with AUCs of 0.869 (95% CI: 0.833–0.905) in the training set and 0.813 (95% CI: 0.745–0.880) in the validation set. For early-stage NSCLC, the model achieved an AUC of 0.809 (95% CI: 0.729–0.890) in the validation set, with a sensitivity of 74.0% and specificity of 81.3% . Multivariate Cox regression identified four AAbs significantly associated with patient prognosis. A prognostic model integrating age and AAb levels demonstrated robust predictive performance for long-term survival (7-year AUC = 0.79) . Bioinformatics analyses further supported the relevance of the corresponding genes/proteins of these AAbs to NSCLC outcomes. Overall, our findings demonstrate that downregulated AAbs possess significant diagnostic and prognostic value in NSCLC and may contribute to improved patient management and survival prediction.  \n1 | Introduction  \nLung cancer (LC) remains a leading cause of cancer incidence and mortality worldwide. In 2022, there were approximately 2.5 million new cases and over 1.8 million deaths globally, accounting for nearly one-eighth (12.4%) of all cancer incidences and nearly  \none-fifth (18.7%) of all cancer-related deaths [1, 2] . Although LC survival and mortality have improved in recent years due to early detection and treatment, it still maintains an unfavorable prognosis, with 5-year survival rates typically below 20%[2, 3] . Studies have shown that NSCLC is the major subtype of LC, mainly including two types: lung adenocarcinoma (LUAD) and  \n\n| Abbreviations: AAbs, autoantibodies; AUC, area under curve; BPN, benign pulmonary nodules; CEA, carcinoembryonic antigen; CI, confidence interval; CNV, Copy number variation; CPTAC, Clinical Proteomic Tumor Analysis Consortium; DM, distant metastasis; ELISA, indirect enzyme-linked immunosorbent assay; GBM, gradient boosting machine; GEO, gene expression omnibus; GO, gene ontology; IgG, immunoglobulin G; LASSO, least absolute shrinkage and selection operator; LC, lung cancer; LM, lymph node metastasis; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NCs, normal controls; NSCLC, non-small cell lung cancer; OD, optical density; OR, odds ratio; OS, overall survival; PPI, protein–protein interaction; SBI, specific binding index; SNR, signal-to-noise ratio; TCGA, The Cancer Genome Atlas. |\n| --- |\n| Thi","cbCaiftMNlYq03Cq","https://ap.wps.com/l/cbCaiftMNlYq03Cq","pdf",11000028,16,"English","# Introduction\n## Study objective and rationale\n## Methods overview (microarray, ELISA, modeling)\n## Diagnostic and prognostic findings","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To identify downregulated autoantibodies in NSCLC and evaluate their diagnostic and prognostic potential as biomarkers.\"},{\"question\":\"How were downregulated autoantibodies discovered?\",\"answer\":\"The study screened NSCLC serum using the HuProt protein microarray, followed by indirect ELISA quantification in 781 samples.\"},{\"question\":\"What modeling approaches were used and what did they show?\",\"answer\":\"Ten machine-learning algorithms were used to build diagnostic models, with gradient boosting achieving the best performance. A prognostic model was further supported by multivariate Cox regression and integration of age with AAb levels.\"}]","The Overlooked Autoantibody Repertoire - Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC | PDF",1790138152,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dfed88c1b03818f8b8cca798607be59.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c454b48cc4c205750ca8eb6c640296e.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e858006026f2c2d27d9cc81465f3ae0.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90f60ee5b7a846c682572d643f0c51a2.webp",980,1287]